FDA Approves Unknown Drug — ALEMBIC
The FDA approved Unknown Drug from ALEMBIC under application ANDA213414 on 2026-06-25.
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
The FDA approved Unknown Drug from ALEMBIC under application ANDA213414 on 2026-06-25.
Mylan Institutional LLC’s June 25, 2026 FDA approval for intravenous ferric carboxymaltose is expected to introduce a generic alternative to the market, potentially reshaping the c…
ScieGen Pharmaceuticals has received FDA approval for its generic version of Tofacitinib Citrate, potentially intensifying price competition in the oral immunosuppressant market. T…
Alembic Pharmaceuticals Limited announced the FDA approval of its ANDA for oseltamivir phosphate oral powder, positioning the company in the market for this essential influenza tre…
Mylan announced the approval of its ANDA under 217076, though specific details regarding the drug substance and route are absent; a formal press release from the manufacturer will …
The FDA approved Unknown Drug from MICRO LABS under application ANDA217238 on 2026-06-24.
Aurobindo Pharma gained approval for its ANDA208746 on June 24, 2026, introducing a generic version of the brand-name drug icosapent ethyl to the market. This regulatory clearance …
Macleods Pharmaceuticals Limited has received FDA approval for its oral Rifapentine generic, allowing for immediate U.S. market entry. This clearance is poised to boost Macleods' n…
Macleods Pharma announced the list date of its pending ANDA application this week, a development expected to diversify its revenue streams and increase the company's competitive st…
On June 23, 2026, ACTAVIS ELIZABETH received FDA approval for generic version ANDA #203611, a move which positions the manufacturer to capitalize on market opportunities in the rel…
NORWICH announced FDA approval for ANDA217449 on June 17, a strategic regulatory milestone that positions the company for potential generic market entry and revenue diversification…
Annora Pharma received FDA approval for its ANDA 219470 application on June 17, 2026, which is expected to diversify the company's generic portfolio and drive incremental revenue s…
Annora Pharma has received final FDA approval for its Abbreviated New Drug Application (ANDA217329), bringing market implications as the generic alternative readies launch pending …
On June 17, 2026, ACTAVIS LABS FL received FDA approval for the brand-name and generic versions of My Health Inc.'s ALDH2 inhibitor, impermexanate, signaling an imminent entry for …
Creekwood Pharmaceuticals has been granted FDA approval for an Abbreviated New Drug Application (ANDA #218875), a regulatory milestone poised to enhance the company’s market share …
1. **Analyze the Request:** * **Topic:** FDA drug approval. * **Details:** * Brand: PERAMPANEL * Generic: PERAMPANEL * Substance: PERAMPA…
Production Development (PROD DEVELOPMENT) announced today the FDA approval of its ANDA 217596, setting the stage for a key generic entry into the market on June 15, 2026. This clea…
Bayer HealthCare Pharmaceuticals has secured FDA approval for AMBELVIST (gadoquatrone), an intravenous drug for obstructive jaundice slated for launch on June 12, 2026. This regula…
Gland Pharma Limited received FDA approval for its ophthalmic solution containing Brimonidine Tartrate and Timolol Maleate, marking a strategic expansion of its generic portfolio. …
The FDA has approved the previously withdrawn version of GADOBUTROL from Zydus Pharmaceuticals USA Inc., increasing competition in the market for this MRI contrast agent and potent…